Research Topic

Drug Prevention and Control of Ventilator-Associated Pneumonia

About this Research Topic

Ventilator-associated pneumonia (VAP) is the second most common nosocomial infection and the leading cause of death from nosocomial infections in critically ill patients, globally. Its incidence ranges from 5% to 67% depending on case mix and the diagnostic criteria used, and the highest rates are in immunocompromised, surgical, and elderly patients. It is estimated that VAP may be responsible for ~27–47% of intensive care unit (ICU) acquired infections. The clinical and economic burden of VAP remains high and the application of existing VAP prevention strategies is variable but disappointing. Therefore, a simple, inexpensive, and safe prevention strategy will contribute to the decrease of VAP occurrence rate and corresponding burden. The pathogenesis of VAP is complicated; however, it typically involves the colonization of upper aerodigestive tract with pathogenic bacteria and the leakage of contaminated oropharyngeal secretions into the lung. Numerous studies have assessed various strategies of VAP prevention which can be classified into pharmacologic and non-pharmacologic interventions. In this
Research Topic, we want to discuss the pharmacologic interventions in order to provide a comprehensive evidences for clinical practice in VAP.

The scope of this Research Topic is the pharmacologic interventions for prevention and/or control of VAP. The types of study that will be accepted are clinical trials (including real word studies), translational animal studies, systematic reviews (including meta-analyses), clinical practice guidelines, modelling studies, pharmacoeconomic studies, methodological studies, and drug resistance studies and must fit within one of the accepted article types for Respiratory Pharmacology. Anyone who is interested in this topic, please contact us.


Keywords: Ventilator-Associated Pneumonia, Drug Prevention, Drug Control


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Ventilator-associated pneumonia (VAP) is the second most common nosocomial infection and the leading cause of death from nosocomial infections in critically ill patients, globally. Its incidence ranges from 5% to 67% depending on case mix and the diagnostic criteria used, and the highest rates are in immunocompromised, surgical, and elderly patients. It is estimated that VAP may be responsible for ~27–47% of intensive care unit (ICU) acquired infections. The clinical and economic burden of VAP remains high and the application of existing VAP prevention strategies is variable but disappointing. Therefore, a simple, inexpensive, and safe prevention strategy will contribute to the decrease of VAP occurrence rate and corresponding burden. The pathogenesis of VAP is complicated; however, it typically involves the colonization of upper aerodigestive tract with pathogenic bacteria and the leakage of contaminated oropharyngeal secretions into the lung. Numerous studies have assessed various strategies of VAP prevention which can be classified into pharmacologic and non-pharmacologic interventions. In this
Research Topic, we want to discuss the pharmacologic interventions in order to provide a comprehensive evidences for clinical practice in VAP.

The scope of this Research Topic is the pharmacologic interventions for prevention and/or control of VAP. The types of study that will be accepted are clinical trials (including real word studies), translational animal studies, systematic reviews (including meta-analyses), clinical practice guidelines, modelling studies, pharmacoeconomic studies, methodological studies, and drug resistance studies and must fit within one of the accepted article types for Respiratory Pharmacology. Anyone who is interested in this topic, please contact us.


Keywords: Ventilator-Associated Pneumonia, Drug Prevention, Drug Control


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

21 November 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

21 November 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top
);